Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials-Reference-Cited by-同舟云学术

Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

Published:2017-10-28 Issue:2 Volume:144 Page:321-335
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Taieb Julien^ORCID,Rivera Fernando,Siena Salvatore,Karthaus Meinolf,Valladares-Ayerbes Manuel,Gallego Javier,Geissler Michael,Koukakis Reija,Demonty Gaston,Peeters Marc

Funder

Amgen

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s00432-017-2534-z/fulltext.html

Reference29 articles.

1. Abad A, Massuti B, Grávalos C, Escudero P, Guillén-Ponce C, Manzano JL, Gomez A, Safont MJ, Gallego J, Sastre J, Pericay C, Dueñas R, López-López C, Losa F, Valladares M, González E, Yuste A, Carrato A, Aranda E, On behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) (2014) Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study. J Clin Oncol 32(Suppl):3560

2. Abad A, Massuti B, Grávalos C, Escudero P, Guillén-Ponce C, Manzano JL, Ortiz MJ, Safont MJ, Gallego J, Sastre J, Pericay C, Dueñas R, Rivera F, Losa F, Valladares-Ayerbes M, González E, Robles L, Aranda E, Carrato A, On behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) ( (2015) Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease. Eur J Cancer 51(Suppl):S374–S375

3. Clarke CN, Kopetz ES (2015) BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol 6:660–667

4. Contal C, O’Quigley J (1999) An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 30:253–270

5. Cremolini C, Loupakis F, Antoniotti C, Lonardi S, Masi G, Salvatore L, Cortesi E, Tomasello G, Spadi R, Zaniboni A, Tonini G, Barone C, Vitello S, Longarini R, Bonetti A, D’Amico M, Di Donato S, Granetto C, Boni L, Falcone A (2015) Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol 26:1188–1194

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of patients with carcinomas in advanced stages with 5-fluorouracil, folinic acid and pyridoxine in tandem;Scientific Reports;2024-05-27

2. Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab;International Journal of Clinical Oncology;2023-06-22

3. Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study;Cancer Medicine;2023-06-16

4. Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212);European Journal of Cancer;2023-01

5. Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab;2022-10-31